Supplements and Compounds Library
Every article, presentation, spotlight, and news item we've tagged to Supplements and Compounds.
Showing 265–288 of 328
Bexorg secures grant to speed Parkinson’s therapies
Bexorg has secured funding to validate TRPML1, a protein target for Parkinson's therapies, using preserved human brain tissue paired with AI-driven biomarker identification. This approach addresses a critical translational gap: the inability to confirm drug efficacy in human neural tissue, which has caused over 95% of CNS drug candidates to fail in clinical trials despite theoretical promise.
Hypoxia-induced autophagic degradation of HIF-1α attenuates cellular aging and extends mammalian lifespan
Intervertebral discs age slowly due to selective autophagy of HIF-1α under naturally hypoxic conditions. A small molecule designed to replicate this mechanism across tissues may extend mammalian lifespan by modulating how cells respond to low-oxygen environments.
Cilia Suppression Reverses Gum Senescence via AKT Activation
Primary cilia accumulation in aged gingival tissue drives fibroblast senescence and periodontal inflammation. Suppressing ciliogenesis reverses this process through AKT signaling activation, offering a mechanistic target for managing age-related gum disease and tissue deterioration.
Chemotherapy Senescence Fuels Metastasis via Fructose Metabolic Reprogramming
Chemotherapy induces senescence in ovarian cancer cells, triggering release of fructose into the cellular environment that reprograms neighboring cancer cells to enhance detachment and metastatic spread. This metabolic coupling mechanism reveals a critical side effect of cancer treatment that can paradoxically promote disease progression through altered membrane cholesterol and energy metabolism.
Transposon’s $22m ARPA-H award to test aging-fighting drug
Transposon Therapeutics received a $22 million ARPA-H grant to study TPN-101, a drug designed to inhibit LINE-1 retrotransposon activity and slow fundamental aging processes rather than treat individual diseases. The approach targets age-related inflammation driven by DNA elements that become dysregulated with age, potentially extending healthspan across multiple conditions simultaneously.
Translation Attenuation Extends Lifespan and Protects Neurons
Atypical tetracyclines extend lifespan and protect neurons from ferroptotic damage by reducing protein synthesis through mechanisms independent of their antibiotic activity. This identifies translation attenuation as a pharmacologically targetable pathway for longevity and neuroprotection across multiple organism models.
The first personalized brain repair for Parkinson’s
Aspen Neuroscience's autologous cell therapy for Parkinson's disease demonstrates early restoration of motor function and quality of life through transplantation of patient-derived dopamine-producing neurons into the brain. This represents a shift from symptomatic management toward biological reconstruction of damaged neural tissue.
Juvenescence advances aging drug to Phase 2 trial
Juvenescence's PAI-1 inhibitor MDI-2517 completed Phase 1 trials, demonstrating safety and tolerability for a once-daily oral therapy targeting inflammation and fibrosis—processes central to aging and age-related disease. Genetic evidence suggests PAI-1 reduction correlates with approximately 10 years of extended lifespan, positioning this mechanism as a meaningful target for aging intervention.
Senescence at the crossroads of postpartum remodeling and tumorigenesis
Cellular senescence plays a dual role in postpartum mammary gland remodeling—supporting normal tissue reorganization while simultaneously creating conditions that enhance tumor progression when oncogenic events coincide with gland involution. This mechanism reveals how a normally protective cellular state becomes pathogenic under specific developmental and genetic circumstances.
ANT1 upregulation advances toward pharmacologic muscle preservation
NorthStrive's AI-driven drug discovery program identified four small-molecule candidates that increased ANT1 protein expression in human skeletal muscle cells by up to 50%, representing early-stage progress toward pharmacological muscle preservation. ANT1 modulation addresses a fundamental constraint in cellular energy metabolism relevant to aging-related muscle decline.
Selective protein degradation targets aggregates in neurodegeneration
TrimTech Therapeutics secured $14 million in additional seed funding to advance protein degradation platforms targeting neurodegenerative disease. The company's approach selectively removes toxic protein aggregates while preserving functional proteins, addressing a mechanistic gap in current neurodegeneration therapies.
Mitorubin, berberrubine-based compounds that improve mitochondrial function, exhibit cardioprotective effects against age-related cardiac dysfunction
Mitorubin, a berberrubine-derived compound, restores mitochondrial function and protects cardiac tissue from age-related deterioration. This addresses a primary mechanism of cardiovascular aging by targeting energy production capacity at the cellular level.
Peptide Pharmacology: Evidence vs. Marketing in Longevity
Peptides represent a therapeutic class with genuine biological activity, requiring the same scrutiny applied to pharmaceutical interventions rather than supplements. The distinction between evidence-supported peptide applications and marketed claims determines whether they function as targeted tools or sources of unquantified risk.
Epia Neuro debuts with stroke-focused BCI
Epia Neuro has launched an implantable brain-computer interface designed to help stroke survivors translate neural intent into functional movement through assistive devices. The approach prioritizes practical restoration of independence in daily life rather than speculative enhancement, addressing a significant gap in post-stroke rehabilitation where functional disability persists across years or decades.
Metal Homeostasis Restores Insulin Sensitivity in Diabetic Model
Telomir-Zn, an investigational compound modulating intracellular metal homeostasis, restored insulin sensitivity in a diet-induced zebrafish diabetes model, with fasting glucose returning to near-control levels and HOMA-IR declining from 10-12 to approximately 3 within 14 days. The preclinical finding demonstrates dose-dependent metabolic restoration through iron-dependent pathway modulation, with potential relevance to both metabolic and oncologic disease.
Transdermal Treprostinil Patch Simplifies PAH Management
Corsair Pharma's Phase 1 trial demonstrates that a transdermal patch delivering an inactive precursor of treprostinil can maintain therapeutic drug levels for 24 hours with acceptable skin tolerability. This delivery innovation addresses a critical burden in pulmonary arterial hypertension management: replacing continuous infusion pumps and indwelling catheters with a once-daily application.
Restoring Lysosomal Clearance Targets Parkinson's Root Cause
Researchers identified a protein mechanism that restores lysosomal clearance of alpha-synuclein, the pathogenic protein in Parkinson's disease. This addresses a fundamental aging problem: the cell's declining ability to eliminate misfolded proteins, which accelerates neurodegeneration when these proteins accumulate and further impair cellular cleanup systems.
Unlimited Bio registers dual gene therapy trial
Unlimited Bio initiated a Phase 1/2a trial combining AAV9-Follistatin and VEGF plasmid gene therapies to address age-related muscle decline, marking the first registered clinical study to combine these two approaches. The dual-therapy strategy targets both muscle growth signaling and vascular support, with safety and functional outcomes tracked over 12 months in adults aged 45 to 75.
GPR40 Activation Reverses Thymic Aging
GPR40 activation via GW9508 restores thymic epithelial cell function in aged mice by suppressing senescence pathways and restoring T-cell production. This addresses immunosenescence—a primary driver of age-related vulnerability to infection, malignancy, and autoimmune dysfunction.
Dynamin‐Related Protein 1‐Dependent Disruption of Mitochondrial Homeostasis Drives Blue Light‐Induced Epithelial‐Mesenchymal Transition in Retinal Aging
Blue light exposure triggers excessive mitochondrial fragmentation in retinal cells through a specific protein (Drp1), driving cellular changes associated with age-related macular degeneration. Blocking this fragmentation restores mitochondrial function and reverses the pathological transformation in both cell cultures and animal models.
Evolve Science launches longevity peptide platform
Evolve Science has launched a peptide and longevity platform that differentiates itself through supply chain transparency and batch-level documentation rather than marketing claims. The company sources products exclusively from FDA-registered US compounding pharmacies and requires Certificates of Analysis for every product, addressing a documented gap in quality verification within the longevity market.
Nuclear senescence precedes neuronal loss in polyglutamine disease
Polyglutamine expansion mutations accelerate nuclear aging pathways independently of neuronal death, revealing that protein misfolding drives cellular senescence before neurons are lost. This finding distinguishes disease mechanisms from cell death, opening intervention points earlier in neurodegeneration progression.
Sphingolipid Restoration Targets Motor Neuron Degeneration in ALS
Leal Therapeutics has initiated a Phase 1/2 clinical trial of LTX-002, an intrathecally delivered antisense oligonucleotide designed to restore sphingolipid balance in the central nervous system of ALS patients. The therapeutic targets SPTLC1 to reduce ceramide accumulation implicated in motor neuron degeneration, addressing a mechanistic driver of both genetic and sporadic ALS.
Unnatural Products inks $1.7b cardiovascular disease collab with Novartis
Unnatural Products and Novartis have partnered to develop macrocyclic peptides—molecular structures between small molecules and biologics—targeting protein interactions implicated in cardiovascular disease and age-related conditions. This approach addresses a critical gap in drug development where conventional therapeutics cannot effectively engage disease-driving targets.